Login
$BCTX
$3.30 -$0.09 (2.65%) Live

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q4 FY2026
As of Jul 31, 2026
Q3 FY2026
As of Apr 30, 2026
Q2 FY2026
As of Jan 31, 2026
Q1 FY2026
As of Oct 31, 2025
Q4 FY2025
As of Jul 31, 2025
Q3 FY2025
As of Apr 30, 2025
Q2 FY2025
As of Jan 31, 2025
Q1 FY2025
As of Oct 31, 2024
Q4 FY2024
As of Jul 31, 2024
Q3 FY2024
As of Apr 30, 2024
Q2 FY2024
As of Jan 31, 2024
Q1 FY2024
As of Oct 31, 2023
Q4 FY2023
As of Jul 31, 2023
Q3 FY2023
As of Apr 30, 2023
Q2 FY2023
As of Jan 31, 2023
Q1 FY2023
As of Oct 31, 2022
Q4 FY2022
As of Jul 31, 2022
ASSETS
CURRENT ASSETS:
Cash and cash equivalents
Amounts receivable
Prepaid expenses
Short-term investments
Amounts receivable and prepaid expenses
Total current assets
NON-CURRENT ASSETS:
Investments
Equity investment in BC Therapeutics
Intangible assets, net
Property and equipment, net
Long term prepaid expenses
Total non-current assets
Total assets
LIABILITIES AND SHAREHOLDERS’ EQUITY
CURRENT LIABILITIES:
Trade payables
Accrued expenses and other payables
Total current liabilities
NON-CURRENT LIABILITIES:
Warrant liability
Total non-current liabilities
SHAREHOLDERS’ EQUITY (DEFICIT):
Share Capital of no par value – Authorized: unlimited at July 31, 2026 and 2025; Issued and outstanding: 8,708,029 and 1,883,906 shares at July 31, 2026 and 2025, respectively
Additional paid in capital
Share-based payment reserve
Warrant reserve
Accumulated other comprehensive loss
Non-controlling interest
Accumulated deficit
Total shareholders’ equity
Total liabilities and shareholders’ equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support